HR 1118, the Value Over Cost Act of 2025, amends federal procurement rules to allow government agencies to select contracts based on "best value" rather than solely the lowest price. It updates sections of the U.S. Code (41 U.S.C. §152 and 10 U.S.C. §3012) to require that contracts first consider the "lowest overall cost," but also permit agencies to choose "best value" when the General Services Administration Administrator determines it serves the government's best interests. This change directly affects federal agencies purchasing goods or services through the Multiple Award Schedule program and defense-related contracts. The bill formalizes an existing practice under federal procurement regulations (FAR §15.101) without altering the underlying definition of "best value."
This bill reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, setting $31 million for fiscal year 2025 and $33 million annually for fiscal years 2027-2031. It also extends the deadline for the national cord blood inventory program from 2026 to 2031. The legislation directly affects stem cell research programs and cord blood banks by maintaining federal funding levels and prolonging the inventory program’s timeline. These provisions ensure continuity for existing research infrastructure and blood bank operations without introducing new policy changes.
This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.
HR 4123, the FIT Procurement Act, modernizes federal information and communications technology (ICT) procurement by requiring new training for federal acquisition staff and streamlining processes to boost small business participation. The bill mandates a cross-functional ICT training program covering cloud computing, AI, cybersecurity, and commercial tech adoption, with learning objectives focused on outcome-based contracting and reducing waste. It increases simplified acquisition thresholds ($250,000 to $500,000) and micro-purchase limits ($10,000 to $25,000) to reduce administrative barriers. The Act also directs the Comptroller General to assess small business participation in federal tech contracts and requires agencies to eliminate unnecessary procedural hurdles for small businesses. These changes directly affect federal procurement staff, small businesses competing for contracts, and executive agencies managing ICT acquisitions.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
HR 2715, the *Destruction of Hazardous Imports Act*, expands the authority to destroy imported goods that pose public health risks. It amends the Federal Food, Drug, and Cosmetic Act to allow the Secretary of Health and Human Services to order the destruction of any refused import (not just drugs or devices) if it presents a significant health concern. The bill also prohibits the unauthorized movement, sale, or export of such refused goods. These changes apply to importers of hazardous refused articles 180 days after enactment, with the FDA required to finalize implementing regulations within 90 days.
HR 2001 increases annual funding for a grant program supporting dental workforce development from $13.9 million to $15 million, extending the program through fiscal years 2026-2030 (previously 2019-2023) under the Public Health Service Act. The bill modifies existing funding levels to maintain support for addressing dental workforce shortages, with funds remaining available until expended. This change directly affects the operation of the grant program and its ability to fund dental workforce initiatives.
This bill requires Medicare to create separate payment codes for ultralightweight manual wheelchairs based on their frame material (specifically titanium or carbon fiber vs. other materials), starting in 2026. It ensures Medicare pays the standard rate for titanium/carbon fiber wheelchairs regardless of material, while allowing suppliers to charge beneficiaries the difference between Medicare's payment and their actual cost. Beneficiaries must receive a notice about potential additional costs before purchasing or renting such wheelchairs. The bill directly affects Medicare beneficiaries needing these specialized wheelchairs and the suppliers who provide them.
This bill reauthorizes and improves federal programs focused on preventing, detecting, and treating traumatic brain injuries (TBIs), extending funding through 2030. It updates CDC surveillance to better track high-risk groups (like military personnel, first responders, and those in certain occupations) and requires public sharing of aggregated TBI data. States receiving grants must maintain non-Federal funding levels for TBI programs, with limited waivers allowed. The bill also mandates a congressional report on high-risk populations and a study examining long-term TBI effects, including links to dementia and mental health conditions.
HR 2913, the Ukraine Support Act, provides comprehensive U.S. support for Ukraine in response to Russia's invasion. The bill authorizes security assistance including lend-lease authority for military equipment, establishes a Ukraine Reconstruction Trust Fund for economic recovery, and imposes new sanctions targeting Russian financial institutions, oil companies, and government officials. It also includes provisions to counter Russian disinformation, support Radio Free Europe, and address the kidnapping of Ukrainian children. The legislation directly affects U.S. foreign policy, Ukraine's defense capabilities, and Russia's access to international financial systems. The act aims to strengthen Ukraine's sovereignty while holding Russia accountable for its actions.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
